Liposomal paclitaxel formulations

Journal of Controlled Release

Volumn 163, Issue 3, 2012, Pages 322-334

  Koudelka, Štěpán ^a   Turánek, Jaroslav ^a,b  

^a VETERINARY RESEARCH INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Anti cancer drugs; Drug delivery systems; Drug targeting; Liposome; Paclitaxel

Indexed keywords

ANTICANCER DRUG; CLINICAL TESTING; CLINICAL TRIAL; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; DRUG-TARGETING; HYPERSENSITIVITY REACTION; IN-VIVO; LIPOSOMAL FORMULATION; MAXIMUM TOLERATED DOSE; OVARIAN CANCERS; PACLITAXEL; PHASE II; SIDE EFFECT; TAXANES; TUMOR MODELS;

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; EXPERIMENTS; LIPOSOMES;

DRUG INTERACTIONS;

CREMOPHOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR; HYALURONIC ACID; LIPOSOME; LIPUSU; MAGNETITE NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; EMBRYOTOXICITY; ENCAPSULATION; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HEART RHYTHM; HEAT SENSITIVITY; HUMAN; HYPESTHESIA; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; LIPOSOMES; NEOPLASMS; PACLITAXEL;

EID: 84867366635     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.09.006     Document Type: Review

References (109)

1. L.B. Michaud, V. Valero, and G. Hortobagyi Risks and benefits of taxanes in breast and ovarian cancer Drug Saf. 23 2000 401 428
2. M.C. Wani, H.L. Taylor, M.E. Wall, P. Coggon, and A.T. McPhail Plant antitumor agents 6. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus Brevifolia J. Am. Chem. Soc. 93 1971 2325 2327
3. E.K. Rowinsky, and R.C. Donehower Drug therapy - Paclitaxel (Taxol) N. Engl. J. Med. 332 1995 1004 1014
4. I. Kramer, and A. Heuser Paclitaxel pharmaceutical and pharmacological issues Eur. Hosp. Pharm. 1 1995 37 41
5. R.T. Dorr Pharmacology and toxicology of Cremophor EL diluent Ann. Pharmacother. 28 1994 511 514
6. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. Baker, D.A. Vanecho, D.D. Vonhoff, and B. Leylandjones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1990 1263 1268 (Pubitemid 20195638)
7. M.C. Allwood, and H. Martin The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection Int. J. Pharm. 127 1996 65 71 (Pubitemid 26069153)
8. S.C. Kim, H.J. Yoon, J.W. Lee, J.W. Yu, E.S. Park, and S.C. Chi Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles Int. J. Pharm. 293 2005 303 310 (Pubitemid 40381102)
9. Q.Y. Xu, L.A. Trissel, and J.F. Martinez Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22 or 32 degrees C Am. J. Hosp. Pharm. 51 1994 3058 3060
10. S.C. Lee, C. Kim, I.C. Kwon, H. Chung, and S.Y. Jeong Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel J. Control. Release 89 2003 437 446 (Pubitemid 36555903)
11. X. Feng, Y.J. Yuan, and J.C. Wu Synthesis and evaluation of water-soluble paclitaxel prodrugs Bioorg. Med. Chem. Lett. 12 2002 3301 3303 (Pubitemid 35248235)
12. F. Dosio, S. Arpicco, P. Brusa, B. Stella, and L. Cattel Poly(ethylene glycol) human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics J. Control. Release 76 2001 107 117 (Pubitemid 32786889)
13. C.H. Liu, J.S. Strobl, S. Bane, J.K. Schilling, M. McCracken, S.K. Chatterjee, R. Rahim-Bata, and D.G.I. Kingston Design, synthesis and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer J. Nat. Prod. 67 2004 152 159 (Pubitemid 38282901)
14. B.B. Lundberg, V. Risovic, M. Ramaswamy, and K.M. Wasan A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration J. Control. Release 86 2003 93 100 (Pubitemid 35461976)
15. G. Ruan, and S.S. Feng Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel Biomaterials 24 2003 5037 5044 (Pubitemid 37242983)
16. U.S. Sharma, S.V. Balasubramanian, and R.M. Straubinger Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins J. Pharm. Sci. 84 1995 1223 1230
17. E. Merisko-Liversidge, P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, J. Rake, J.M. Shaw, S. Pugh, L. Polin, J. Jones, T. Corbett, E. Cooper, and G.G. Liversidge Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Pharm. Res. 13 1996 272 278 (Pubitemid 26074194)
18. A. Sharma, and U.S. Sharma Liposomes in drug delivery: progress and limitations Int. J. Pharm. 154 1997 123 140 (Pubitemid 27351317)
19. R.D. Hofheinz, S.U. Gnad-Vogt, U. Beyer, and A. Hochhaus Liposomal encapsulated anticancer drugs Anticancer Drugs 16 2005 691 707
20. S. Koudelka, J. Masek, J. Neuzil, and J. Turanek Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation J. Pharm. Sci. 99 2010 2434 2443
21. M. Tattersall, and S. Clarke Developments in drug delivery: implications for cancer care Curr. Opin. Oncol. 15 2003 293 299 (Pubitemid 36994033)
22. S.B. Kulkarni, G.V. Betageri, and M. Singh Factors affecting microencapsulation of drugs in liposomes J. Microencapsul. 12 1995 229 246
23. S.V. Balasubramanian, and R.M. Straubinger Taxol-lipid interactions - taxol-dependent effects on the physical properties of model membranes Biochemistry 33 1994 8941 8947 (Pubitemid 24258002)
24. C. Bernsdorff, R. Reszka, and R. Winter Interaction of the anticancer agent Taxol (TM) (paclitaxel) with phospholipid bilayers J. Biomed. Mater. Res. 46 1999 141 149
25. M.R. Wenk, A. Fahr, R. Reszka, and J. Seelig Paclitaxel partitioning into lipid bilayers J. Pharm. Sci. 85 1996 228 231 (Pubitemid 26055806)
26. R.M. Straubinger, and S.V. Balasubramanian Preparation and characterization of taxane-containing liposomes Methods Enzymol. 391 2005 97 117 (Pubitemid 40259698)
27. G.N. Kumar, U.K. Walle, K.N. Bhalla, and T. Walle Binding of taxol to human plasma, albumin and alpha-1-acid glycoprotein Res. Commun. Chem. Pathol. Pharmacol. 80 1993 337 344 (Pubitemid 23187695)
28. E. Sykes, K. Woodburn, D. Decker, and D. Kessel Effects of Cremophor-EL on distribution of taxol to serum lipoproteins Br. J. Cancer 70 1994 401 404 (Pubitemid 24268537)
29. A. Sparreboom, O. van Tellingen, W.J. Nooijen, and J.H. Beijnen Tissue distribution, metabolism and excretion of paclitaxel in mice Anticancer Drugs 7 1996 78 86 (Pubitemid 26059949)
30. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, B. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 1999 1454 1457 (Pubitemid 29160110)
31. M.D. Wild, U.K. Walle, and T. Walle Extensive and saturable accumulation of paclitaxel by the human platelet Cancer Chemother. Pharmacol. 36 1995 41 44
32. G.J. Fetterly, T.H. Grasela, J.W. Sherman, J.L. Dul, A. Grahn, D. Lecomte, J. Fiedler-Kelly, N. Damjanov, M. Fishman, M.P. Kane, E.H. Rubin, and A.R. Tan Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel Clin. Cancer Res. 14 2008 5856 5863
33. G.J. Fetterly, and R.M. Straubinger Pharmacokinetics of paclitaxel-containing liposomes in rats AAPS PharmSci 5 2003
34. T.M. Allen, and C. Hansen Pharmacokinetics of stealth versus conventional liposomes - effect of dose BBA-Biomembr. 1068 1991 133 141
35. F. Sampedro, J. Partika, P. Santalo, A.M. Molinspujol, J. Bonal, and R. Perez-Soler Liposomes as carriers of different new lipophilic antitumor drugs - a preliminary report J. Microencapsul. 11 1994 309 318 (Pubitemid 24148440)
36. A. Sharma, E. Mayhew, and R.M. Straubinger Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model Cancer Res. 53 1993 5877 5881 (Pubitemid 24006153)
37. M.F. Shieh, I.M. Chu, C.J. Lee, P. Kan, D.M. Hau, and J.J. Shieh Liposomal delivery system for taxol J. Ferment. Bioeng. 83 1997 87 90 (Pubitemid 27091612)
38. T. Yang, F.D. Cui, M.K. Choi, H.X. Lin, S.J. Chung, C.K. Shim, and D.D. Kim Liposome formulation of paclitaxel with enhanced solubility and stability Drug Deliv. 14 2007 301 308 (Pubitemid 47027038)
39. M. Heney, M. Alipour, D. Vergidis, A. Omri, C. Mugabe, J. Thang, and Z. Suntres Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells Can. J. Physiol. Pharmacol. 88 2010 1172 1180
40. A. Sharma, E. Mayhew, L. Bolcsak, C. Cavanaugh, P. Harmon, A. Janoff, and R.J. Bernacki Activity of paclitaxel liposome formulations against human ovarian tumor xenografts Int. J. Cancer 71 1997 103 107 (Pubitemid 27158416)
41. C. Holvoet, Y.V. Heyden, G. Lories, and J. Plaizier-Vercammen Preparation and evaluation of paclitaxel-containing liposomes Pharmazie 62 2007 126 132 (Pubitemid 46279964)
42. J.A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, and I. Ahmad Development and characterization of a novel Cremophor (R) EL free liposome-based paclitaxel (LEP-ETU) formulation Eur. J. Pharm. Biopharm. 59 2005 177 187 (Pubitemid 39573451)
43. N.V. Koshkina, J.C. Waldrep, L.E. Roberts, E. Golunski, S. Melton, and V. Knight Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model Clin. Cancer Res. 7 2001 3258 3262 (Pubitemid 32963851)
44. D. Needham, and R.S. Sarpal Binding of paclitaxel to lipid interfaces: correlations with interface compliance J. Liposome Res. 8 1998 147 163 (Pubitemid 28268259)
45. S. Koudelka, P. Turanek-Knotigova, J. Masek, Z. Korvasova, M. Skrabalova, J. Plockova, E. Bartheldyova, and J. Turanek Liposomes with high encapsulation capacity for paclitaxel: preparation, characterisation and in vivo anticancer effect J. Pharm. Sci. 99 2010 2309 2319
46. M.C. Woodle, and D.D. Lasic Sterically stabilized liposomes BBA-Biomembr. 1113 1992 171 199
47. P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, and G.Z. Zhu Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time FEBS Lett. 386 1996 243 246 (Pubitemid 26173078)
48. R.K. Jain Transport of molecules across tumor vasculature Cancer Metastasis Rev. 6 1987 559 593
49. H. Maeda, and Y. Matsumura Tumoritropic and lymphotropic principles of macromolecular drugs Crit. Rev. Ther. Drug Carrier Syst. 6 1989 193 210 (Pubitemid 20065994)
50. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft - molecular-size dependence and cutoff size Cancer Res. 55 1995 3752 3756
51. M.L. Immordino, P. Brusa, S. Arpicco, B. Stella, F. Dosio, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel J. Control. Release 91 2003 417 429 (Pubitemid 36980659)
52. P. Crosasso, M. Ceruti, P. Brusa, S. Arpicco, F. Dosio, and L. Cattel Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes J. Control. Release 63 2000 19 30 (Pubitemid 30046939)
53. T. Yang, F.D. Cui, M.K. Choi, J.W. Cho, S.J. Chung, C.K. Shim, and D.D. Kim Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation Int. J. Pharm. 338 2007 317 326 (Pubitemid 46777245)
54. P. Kan, C.W. Tsao, A.J. Wang, W.C. Su, H.F. Liang, A liposomal formulation able to incorporate a high content of paclitaxel and exert promising anticancer effect, J. Drug Deliv. (in press), http://dx.doi.org/10.1155/2011/ 629234.
55. Y. Yoshizawa, Y. Kono, K. Ogawara, T. Kimura, and K. Higaki PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy Int. J. Pharm. 412 2011 132 141
56. Y. Huang, X.M. Chen, B.X. Zhao, X.Y. Ke, B.J. Zhao, X. Zhao, Y. Wang, X.A. Zhang, and Q. Zhang Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo AAPS PharmSciTech 11 2010 752 759
57. S. Zalipsky, C.B. Hansen, D.E.L. deMenezes, and T.M. Allen Long-circulating, polyethylene glycol-grafted immunoliposomes J. Control. Release 39 1996 153 161 (Pubitemid 26194215)
58. P. Sapra, and T.M. Allen Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 42 2003 439 462 (Pubitemid 36700404)
59. J. Wu, Q. Liu, and R.J. Lee A folate receptor-targeted liposomal formulation for paclitaxel Int. J. Pharm. 316 2006 148 153 (Pubitemid 43786219)
60. T. Yang, M.K. Choi, F.D. Cui, J.S. Kim, S.J. Chung, C.K. Shim, and D.D. Kim Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome J. Control. Release 120 2007 169 177 (Pubitemid 47061489)
61. T. Yang, M.K. Choi, F.D. Cui, S.J. Lee, S.J. Chung, C.K. Shim, and D.D. Kim Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells Pharm. Res. 24 2007 2402 2411 (Pubitemid 350060715)
62. S.Y. Meng, B. Su, W. Li, Y.M. Ding, L.A. Tang, W. Zhou, Y. Song, H.Y. Li, and C.C. Zhou Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes Nanotechnology 21 2010
63. S.Y. Meng, B. Su, W. Li, Y.M. Ding, L.A. Tang, W. Zhou, Y. Song, and C.C. Zhou Integrin-targeted paclitaxel nanoliposomes for tumor therapy Med. Oncol. 28 2011 1180 1187
64. H. Zhao, J.C. Wang, Q.S. Sun, C.L. Luo, and Q. Zhang RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer J. Drug Target. 17 2009 10 18
65. T. Terada, M. Mizobata, S. Kawakami, F. Yamashita, and M. Hashida Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes J. Control. Release 119 2007 262 270 (Pubitemid 46770875)
66. X.H. Wang, L.Y. Deng, X.A. Chen, H.Y. Pei, L.L. Cai, X. Zhao, Y.Q. Wei, and L.J. Chen Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice J. Pharm. Sci. 100 2011 1196 1205
67. P.Q. Zhao, H.J. Wang, M. Yu, S.Z. Cao, F. Zhang, J. Chang, and R.F. Niu Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation Pharm. Res. 27 2010 1914 1926
68. R.F. Niu, P.Q. Zhao, Y.J. Yuan, S.Z. Cao, F. Zhang, and J. Chang Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes J. Drug Target. 19 2011 373 381
69. D. Peer, and R. Margalit Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia 6 2004 343 353 (Pubitemid 38924849)
70. V.M. Platt, and F.C. Szoka Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor Mol. Pharm. 5 2008 474 486
71. N. Yerushalmi, and R. Margalit Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites Arch. Biochem. Biophys. 349 1998 21 26 (Pubitemid 28368386)
72. A. Bartolazzi, R. Peach, A. Aruffo, and I. Stamenkovic Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor-development J. Exp. Med. 180 1994 53 66 (Pubitemid 24181055)
73. M.B. Penno, J.T. August, S.B. Baylin, M. Mabry, R.I. Linnoila, V.S. Lee, D. Croteau, X.L. Yang, and C. Rosada Expression of CD44 in human lung-tumor Cancer Res. 54 1994 1381 1387
74. I. Rivkin, K. Cohen, J. Koffler, D. Melikhov, D. Peer, and R. Margalit Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors Biomaterials 31 2010 7106 7114
75. T. Boehm, J. Folkman, T. Browder, and M.S. O'Reilly Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 1997 404 407 (Pubitemid 28027321)
76. J. Denekamp Endothelial cell-proliferation as a novel approach to targeting tumor therapy Br. J. Cancer 45 1982 136 139 (Pubitemid 12207761)
77. J. Denekamp The tumour microcirculation as a target in cancer therapy: a clearer perspective Eur. J. Clin. Invest. 29 1999 733 736 (Pubitemid 29425513)
78. G. Thurston, J.W. Mclean, M. Rizen, P. Baluk, A. Haskell, T.J. Murphy, D. Hanahan, and D.M. McDonald Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice J. Clin. Invest. 101 1998 1401 1413 (Pubitemid 28166838)
79. M. Schmitt-Sody, S. Strieth, S. Krasnici, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, and M. Dellian Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy Clin. Cancer Res. 9 2003 2335 2341 (Pubitemid 36687660)
80. R. Kunstfeld, G. Wickenhauser, U. Michaelis, M. Teifel, W. Umek, K. Naujoks, K. Wolff, and P. Petzelbauer Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a humanized SCID mouse model J. Invest. Dermatol. 120 2003 476 482 (Pubitemid 36298435)
81. S. Streith, M.E. Eichhorn, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, and M. Dellian Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature Int. J. Cancer 110 2004 117 124 (Pubitemid 38507211)
82. C. Bode, L. Trojan, C. Weiss, B. Kraenzlin, U. Michaelis, M. Teifel, P. Alken, and M.S. Michel Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer Oncol. Rep. 22 2009 321 326
83. D. Sharma, T.P. Chelvi, and R. Ralhan Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma Melanoma Res. 8 1998 240 244 (Pubitemid 28313761)
84. S.F. Nie, W.L.W. Hsiao, W.S. Pan, and Z.J. Yang Thermoreversible pluronic (R) F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies Int. J. Nanomedicine 6 2011 151 166
85. J.Q. Zhang, Z.R. Zhang, H. Yang, Q.Y. Tan, S.R. Qin, and X.L. Qiu Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies Pharm. Res. 22 2005 573 583 (Pubitemid 40603255)
86. M.J. Kim, D.H. Jang, Y.I. Lee, H.S. Jung, H.J. Lee, and Y.H. Choa Preparation, characterization, cytotoxicity and drug release behavior of liposome-enveloped paclitaxel/Fe(3)O(4) nanoparticles J. Nanosci. Nanotechnol. 11 2011 889 893
87. A. Cabanes, K.E. Briggs, P.C. Gokhale, J.A. Treat, and A. Rahman Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel Int. J. Oncol. 12 1998 1035 1040 (Pubitemid 28186763)
88. A. Sharma, R.M. Straubinger, I. Ojima, and R.J. Bernacki Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice J. Pharm. Sci. 84 1995 1400 1404
89. M.H. Bartoli, M. Boitard, H. Fessi, H. Beriel, J.P. Devissaguet, F. Picot, and F. Puisieux In vitro and in vivo antitumoral activity of free, and encapsulated taxol J. Microencapsul. 7 1990 191 197 (Pubitemid 20224139)
90. A. Sharma, U.S. Sharma, and R.M. Straubinger Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia Cancer Lett. 107 1996 265 272 (Pubitemid 26381999)
91. A. Sharma, and R.M. Straubinger Novel taxol formulations - preparation and characterization of taxol-containing liposomes Pharm. Res. 11 1994 889 896 (Pubitemid 24210627)
92. R.M. Straubinger, A. Sharma, M. Murray, and E. Mayhew Novel taxol formulations: taxol-containing liposomes J. Natl. Cancer Inst. Monogr. 15 1993 69 78
93. A.R. Scialli, J.M. Desesso, A. Rahman, S.R. Husain, and G.C. Goeringer Embryotoxicity of free and liposome-encapsulated taxol in the chick Pharmacology 51 1995 145 151
94. A.R. Scialli, T.B. Waterhouse, J.M. Desesso, A. Rahman, and G.C. Goeringer Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat Teratology 56 1997 305 310 (Pubitemid 28035176)
95. O. Soepenberg, A. Sparreboom, M.J.A. de Jonge, A.S.T. Planting, G. de Heus, W.J. Loos, C.M. Hartman, C. Bowden, and J. Verweij Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome with solid encapsulated paclitaxel in patients tumours Eur. J. Cancer 40 2004 681 688 (Pubitemid 38326617)
96. N. Damjanov, M.N. Fishman, J.L. Steinberg, G.J. Fetterly, A. Haas, A. Grahn, C. Lauay, J.L. Dul, J.W. Sherman, and E.H. Rubin Final results of a phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer J. Clin. Oncol. 23 2005 147
97. M.N. Fishman, Y. Elsayed, N. Damjanov, J.L. Steinberg, J.J. Mahany, J.A. Nieves, S.P. Wanaski, J.L. Dul, and J.W. Sherman Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer J. Clin. Oncol. 22 2004 154
98. M.N. Fishman, Y.A. Elsayed, N. Damjanov, J.L. Steinberg, J.J. Mahany, J.A. Nieves, S.P. Wanaski, J.L. Dul, and J.W. Sherman Safety and tolerability of liposome entrapped paclitaxel (LEP-ETU) administered with and without premedication in patients with advanced cancer Ann. Oncol. 15 2004 108
99. A.R. Tan, A.R. Hanauske, H. Gelderblom, M.E. Scheulen, L.J. Van Warmerdam, H. Rosing, G.J. Fetterly, V.S. Shu, J.W. Sherman, and E.H. Rubin Results of a clinical pharmacokinetic (PK) bioequiulence (BE) study of liposomal paclitaxel (LEP-ETU) versus paclitaxel (T) in patients with advanced cancer J. Clin. Oncol. 24 2006 83
100. NeoPharm presents the phase II data of liposome-entrapped paclitaxel (LEP) in patients with metastatic breast cancer http://www.drugs.com/clinical- trials/neopharm-presents-phase-ii-data-liposome-entrapped-paclitaxel-lep- patients-metastatic-breast-cancer-8759.html (24-3-2012)
101. S. Strieth, C.F. Nussbaum, M.E. Eichhorn, M. Fuhrmann, M. Teifel, U. Michaelis, A. Berghaus, and M. Dellian Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes Int. J. Cancer 122 2008 452 460 (Pubitemid 350234735)
102. M. Christopeit, G. Lenz, R. Forstpointner, K. Bartelheim, R. Kuhnbach, K. Naujoks, and A. Schalhorn Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma Chemotherapy 54 2008 309 314
103. U. Fasol, A. Frost, M. Buchert, J. Arends, U. Fiedler, D. Schan, J. Scheuenpflug, and K. Mross Vascular and pharmacokinetic effects of EndoTAG/1 in patients with advanced cancer and liver metastasis Ann. Oncol. 23 2012 1030 1036
104. Q. Zhang, X.E. Huang, and L.L. Gao A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors Biomed. Pharmacother. 63 2009 603 607
105. X.H. Wang, J.C. Zhou, Y.S. Wang, Z.Y. Zhu, Y. Lu, Y.Q. Wei, and L.J. Chen A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions Eur. J. Cancer 46 2010 1474 1480
106. X.H. Wang, H. Zheng, Z.Y. Zhu, Y.Q. Wei, and L.J. Chen Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography J. Pharm. Sci. 99 2010 4746 4752
107. FDA approval for nanoparticle paclitaxel http://www.cancer.gov/ cancertopics/druginfo/fda-nanoparticle-paclitaxel (24-3-2012)
108. K. Garber Improved paclitaxel formulation hints at new chemotherapy approach J. Natl. Cancer Inst. 96 2004 90 91 (Pubitemid 38195893)
109. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803 (Pubitemid 46657376)